BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

905 related articles for article (PubMed ID: 18840783)

  • 21. Fasudil improves the endothelial dysfunction in the aorta of spontaneously hypertensive rats.
    Tsounapi P; Saito M; Kitatani K; Dimitriadis F; Ohmasa F; Shimizu S; Kinoshita Y; Takenaka A; Satoh K
    Eur J Pharmacol; 2012 Sep; 691(1-3):182-9. PubMed ID: 22819709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of RhoA/ROCK1 signaling pathway in hyperglycemia-induced microvascular endothelial dysfunction in diabetic retinopathy.
    Lu QY; Chen W; Lu L; Zheng Z; Xu X
    Int J Clin Exp Pathol; 2014; 7(10):7268-77. PubMed ID: 25400825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy.
    Hollanders K; Hove IV; Sergeys J; Bergen TV; Lefevere E; Kindt N; Castermans K; Vandewalle E; van Pelt J; Moons L; Stalmans I
    Curr Eye Res; 2017 Feb; 42(2):260-272. PubMed ID: 27399806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses isoproterenol-induced heart failure in rats via JNK and ERK1/2 pathways.
    Wang N; Guan P; Zhang JP; Li YQ; Chang YZ; Shi ZH; Wang FY; Chu L
    J Cell Biochem; 2011 Jul; 112(7):1920-9. PubMed ID: 21433064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of Rho kinase protects from ischaemia-reperfusion injury via regulation of arginase activity and nitric oxide synthase in type 1 diabetes.
    Tratsiakovich Y; Kiss A; Gonon AT; Yang J; Sjöquist PO; Pernow J
    Diab Vasc Dis Res; 2017 May; 14(3):236-245. PubMed ID: 28183205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Rho-kinase by fasudil restores the cardioprotection of ischemic postconditioninng in hypercholesterolemic rat heart.
    Wu N; Li W; Shu W; Lv Y; Jia D
    Mol Med Rep; 2014 Nov; 10(5):2517-24. PubMed ID: 25231456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RhoA/ROCK may involve in cardiac hypertrophy induced by experimental hyperthyroidism.
    Na W; Peng G; Jianping Z; Yanzhong C; Shengjiang G; Li C
    Toxicol Ind Health; 2012 Oct; 28(9):831-9. PubMed ID: 22072613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis.
    Anegawa G; Kawanaka H; Yoshida D; Konishi K; Yamaguchi S; Kinjo N; Taketomi A; Hashizume M; Shimokawa H; Maehara Y
    Hepatology; 2008 Mar; 47(3):966-77. PubMed ID: 18167063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Could pharmacological curtailment of the RhoA/Rho-kinase pathway reverse the endothelial barrier dysfunction associated with Ebola virus infection?
    Eisa-Beygi S; Wen XY
    Antiviral Res; 2015 Feb; 114():53-6. PubMed ID: 25512227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fasudil, a Rho-associated protein kinase inhibitor, attenuates retinal ischemia and reperfusion injury in rats.
    Song H; Gao D
    Int J Mol Med; 2011 Aug; 28(2):193-8. PubMed ID: 21455561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
    Kolavennu V; Zeng L; Peng H; Wang Y; Danesh FR
    Diabetes; 2008 Mar; 57(3):714-23. PubMed ID: 18083785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic Rho-kinase inhibition improves left ventricular contractile dysfunction in early type-1 diabetes by increasing myosin cross-bridge extension.
    Waddingham MT; Edgley AJ; Astolfo A; Inagaki T; Fujii Y; Du CK; Zhan DY; Tsuchimochi H; Yagi N; Kelly DJ; Shirai M; Pearson JT
    Cardiovasc Diabetol; 2015 Jul; 14():92. PubMed ID: 26194354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term administration of fasudil improves cardiomyopathy in streptozotocin-induced diabetic rats.
    Guan SJ; Ma ZH; Wu YL; Zhang JP; Liang F; Weiss JW; Guo QY; Wang JY; Ji ES; Chu L
    Food Chem Toxicol; 2012 Jun; 50(6):1874-82. PubMed ID: 22429817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Preventive strategy for the treatment of diabetic vitreoretinopathy].
    Hata Y
    Nippon Ganka Gakkai Zasshi; 2009 Mar; 113(3):379-401; discussion 402. PubMed ID: 19348184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes.
    Zhou H; Fang C; Zhang L; Deng Y; Wang M; Meng F
    Chin Med J (Engl); 2014; 127(2):225-31. PubMed ID: 24438608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium.
    Hamid SA; Bower HS; Baxter GF
    Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2598-606. PubMed ID: 17220176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina.
    Yokota T; Utsunomiya K; Taniguchi K; Gojo A; Kurata H; Tajima N
    Jpn J Ophthalmol; 2007; 51(6):424-30. PubMed ID: 18158592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fasudil alleviates hepatic fibrosis in type 1 diabetic rats: involvement of the inflammation and RhoA/ROCK pathway.
    Xie Y; Song T; Huo M; Zhang Y; Zhang YY; Ma ZH; Wang N; Zhang JP; Chu L
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(17):5665-5677. PubMed ID: 30229844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection.
    Rikitake Y; Kim HH; Huang Z; Seto M; Yano K; Asano T; Moskowitz MA; Liao JK
    Stroke; 2005 Oct; 36(10):2251-7. PubMed ID: 16141422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGR5 receptor activation attenuates diabetic retinopathy through suppression of RhoA/ROCK signaling.
    Zhu L; Wang W; Xie TH; Zou J; Nie X; Wang X; Zhang MY; Wang ZY; Gu S; Zhuang M; Tan J; Shen C; Dai Y; Yang X; Yao Y; Wei TT
    FASEB J; 2020 Mar; 34(3):4189-4203. PubMed ID: 31957105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.